A functional abdominal pain problem is functional dyspepsia (FD). There is a scarcity of information on the economic impact of FD on children. The study’s primary goal was to quantify the annual assessment cost, and our secondary goal was to uncover potential prognostic variables of FD in children. The 136 patients who satisfied the inclusion criteria were split into two clinical groups: complete improvement and partial/no improvement. Medications were described in detail. The cost of an annual assessment was estimated using Medicare reimbursement rates from 2017. In all, the annual evaluation cost $724.874 $180.075 for all patients. The annual cost of evaluating children with FD is estimated to be $5.79 billion. PIG/NIG had a substantially greater average number of clinic visits, period of follow-up in months, utilization of imaging investigations, and endoscopic procedures. In comparison to CIG, PIG/NIG required numerous medicines to manage symptoms. The probability of receiving a complete answer increased by 0.998 for every $500 decrease in overall evaluation cost. There were no predictive variables found in children with FD.

Children’s FD has a huge economic influence on healthcare spending. Patients with FD who have a partial or no response to therapy face a higher financial burden, potentially increasing healthcare costs.